IR@PKUHSC  > 北京大学第二临床医学院  > 肝胆外科
学科主题临床医学
Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study
Huang, Lei; Li, Guang-ming; Zhu, Ji-ye; Li, Zhao; Li, Tao; Leng, Xi-sheng
关键词Follow Up Recurrence Targeted Therapy Chemotherapy Survival Rate Side Effect
刊名ONCOTARGETS AND THERAPY
2012
DOI10.2147/OTT.S31387
5页:457-462
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Biotechnology & Applied Microbiology ; Oncology
研究领域[WOS]Biotechnology & Applied Microbiology ; Oncology
关键词[WOS]ADVANCED HEPATOCELLULAR-CARCINOMA ; THERAPY
英文摘要

Background: The purpose of this study was to determine the efficacy of sorafenib in preventing and treating tumor recurrence after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria.

Methods: Thirty patients with primary hepatic carcinoma exceeding the Milan criteria underwent liver transplantation at our hospital between March 2008 and June 2010. Matched for age and gender, the patients were randomized to treatment with sorafenib 400 mg bid or capecitabine (control group, 1500 mg bid, administered for 2 weeks followed by a 2-week rest interval in each cycle). Treatments were discontinued 18 months after transplantation if no recurrence occurred. Patients who experienced tumor recurrence continued their allocated treatment until they were deemed no longer suitable for the medication. Sorafenib and capecitabine were stopped or their dose was reduced in patients with severe adverse reactions.

Results: The one-year recurrence rates were 53.3% and 86.6% in patients treated with sorafenib and capecitabine, respectively (chi(2) = 3.968, P < 0.05), and the one-year survival rates were 93.3% and 46.6%, respectively (chi(2) = 7.777, P < 0.05). Mean survival time was significantly longer in the sorafenib group (24.6 +/- 1.7 [range 7-28] months) than in the capecitabine group (16.4 +/- 2.7 [range 5-34], months (chi(2) = 7.154, P < 0.05). Most treatment-emergent adverse reactions in both treatment groups were of grade 1 or 2 in severity. The incidence of diarrhea and hand-foot syndrome tended to be higher in the sorafenib group.

Conclusion: For patients with primary hepatic carcinoma exceeding the Milan criteria, sorafenib may reduce or delay tumor recurrence after liver transplantation and prolong patient survival, with tolerable side effects.

语种英语
WOS记录号WOS:000312481200001
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54527
专题北京大学第二临床医学院_肝胆外科
作者单位Peking Univ, Ctr Hepatobiliary Surg, Peoples Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Huang, Lei,Li, Guang-ming,Zhu, Ji-ye,et al. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study[J]. ONCOTARGETS AND THERAPY,2012,5:457-462.
APA Huang, Lei,Li, Guang-ming,Zhu, Ji-ye,Li, Zhao,Li, Tao,&Leng, Xi-sheng.(2012).Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study.ONCOTARGETS AND THERAPY,5,457-462.
MLA Huang, Lei,et al."Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study".ONCOTARGETS AND THERAPY 5(2012):457-462.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Huang, Lei]的文章
[Li, Guang-ming]的文章
[Zhu, Ji-ye]的文章
百度学术
百度学术中相似的文章
[Huang, Lei]的文章
[Li, Guang-ming]的文章
[Zhu, Ji-ye]的文章
必应学术
必应学术中相似的文章
[Huang, Lei]的文章
[Li, Guang-ming]的文章
[Zhu, Ji-ye]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。